PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34504610-2	2021	The present study aimed to investigate whether angiotensin-converting enzyme 2 (ACE2) could regulate FAK and alleviate PAH in a rat model of PAH established with a single administration of monocrotaline followed by continuous hypoxia treatment.	Monocrotaline	189-202	angiotensin I converting enzyme 2	Rattus norvegicus	47-78	
19246717-4	2009	OBJECTIVES: We have taken advantage of a recently discovered synthetic activator of ACE2, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), to study its effects on monocrotaline-induced PH in rats to support this hypothesis.	Monocrotaline	224-237	angiotensin I converting enzyme 2	Rattus norvegicus	84-88	
31931441-5	2020	Oral gavage of monocrotaline-induced PAH rats resulted in dose-dependent delivery of ANG-(1-7) and ACE2 in plasma/tissues and PAH development was attenuated with decreases in right ventricular (RV) hypertrophy, RV systolic pressure, total pulmonary resistance and pulmonary artery remodeling.	Monocrotaline	15-28	angiotensin I converting enzyme 2	Rattus norvegicus	99-103	
25275723-3	2015	Here we identified a novel ACE2 activator and investigated how the compound reduced monocrotaline (MCT)-induced PH.	Monocrotaline	84-97	angiotensin I converting enzyme 2	Rattus norvegicus	27-31	
25275723-3	2015	Here we identified a novel ACE2 activator and investigated how the compound reduced monocrotaline (MCT)-induced PH.	Monocrotaline	99-102	angiotensin I converting enzyme 2	Rattus norvegicus	27-31	
25275723-9	2015	Interestingly, NCP-2454 increased the relative expression of ACE2 and MAS mRNA in lung tissue, especially in MCT-treated rats.	Monocrotaline	109-112	angiotensin I converting enzyme 2	Rattus norvegicus	61-65